Use one of the services below to sign in to PBS: You've just tried to add this video to My List. But first, we need you to sign in to PBS using one of the services below. You've just tried to add this ...
The study included 31,900 infants, 49.1% of whom received nirsevimab. HealthDay News — Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower ...
Health-related quality of life (HRQoL) in children with interstitial lung disease (ILD) is strongly influenced by clinical and developmental factors such as recent hospitalizations and poor growth, ...
Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides effective protection against respiratory syncytial virus-related lower respiratory ...
ENFLONSIA is a preventive monoclonal antibody designed to protect infants against a spectrum of RSV disease severity, including worsening disease requiring hospitalization ENFLONSIA is the first and ...
Nirsevimab was linked to fewer RSV hospitalizations and severe outcomes in newborns. Read more about this study.
Reducing dampness through housing upgrades lowers respiratory medication use, offering strong evidence for health benefits of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results